Li Li

Li Li

Auto-generated profile, based on publicly available information

Li Li

Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing Medical University Affiliated Cancer Hospital, Nanjing 210009, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Biosensors and Bioelectronics
Verified
Journal Article
Closed access
LWLin Wang
Lin Wang
HLHao Li
Hao Li
LSLiu Shi
Liu Shi
LLLi Li
Li Li
FJFengjie Jia
Fengjie Jia
GLGenxi Li
Genxi Li

12 January 2022 in Computational and Mathematical Methods in Medicine
Verified
Journal Article
Open access
PDF file
LLLi Li
Li Li
DWDa Wei
Da Wei
JZJunying Zhang
Junying Zhang
RDRong Deng
Rong Deng
JTJinhai Tang
Jinhai Tang
DSDongming Su
Dongming Su
Objective. Studies revealed an important role of microRNAs (miRNAs) in multiple cancers, including breast cancer. In the present study, we evaluated the role and function of miR-641 in breast cancer. Methods. The expression level of miR-641 in breast cancer cell lines (Hs-578T, MCF7, HCC1937, and MAD-MB-231) was determined by real-time PCR. Functional analyses, including CCK-8 assay, transwell assay, wound-healing assay, and apoptosis detection, were carried out to explore the roles of miRNA-641 in malignant behaviors of breast cancer. Luciferase report assay was used to investigate the regulatory association of miRNA-641 with its potential targets. Results. The expression levels of miR-641 were downregulated, while the expression levels of nuclear casein kinase and cyclin-dependent kinase substrate 1 (NUCKS1) were increased in breast cancer cell lines. The in vitro results showed that miR-641 repressed proliferation and migration/invasion and promoted apoptosis of breast cancer cells. NUCKS1, a positive regulator of phosphatidylinositol-3-kinases (PI3K)/protein-serine-threonine kinase (AKT) pathway, was confirmed as a direct target of miR-641. The of treatment of the PI3K agonist, 740Y-P, could abrogate the antioncogenic potentials of miR-641 in breast cancer cells. Conclusion. miR-641 functioned as a tumor suppressor through the PI3K/AKT signaling pathway via targeting NUCKS1 in breast cancer.

7 January 2022 in Journal of Clinical Laboratory Analysis
Verified
Journal Article
Open access
PDF file
CMChangfei Mao
Changfei Mao
MWMin Wang
Min Wang
LLLi Li
Li Li
JTJinhai Tang
Jinhai Tang
Human epidermal growth factor receptor 2 (HER2)‐positive is a particularly aggressive type of the breast cancer. Trastuzumab‐based therapy is a standard treatment for HER2‐positive breast cancer, but some patients are resistance to the therapy. There are no known diagnostic biomarkers to improve the early diagnosis of HER2‐positive breast cancer and the clinical utility of trastuzumab therapy. Using ultrahigh‐performance liquid time of flight mass spectrometry (UPLC‐TOF‐MS)‐based serum metabolomics and multivariate statistical analysis, we investigated and identified the circulating metabolites L‐arginine and arachidonic acid were elevated in trastuzumab‐responsive and trastuzumab‐resistant HER2‐positive breast cancer patients, and increased until reaching their peaks in trastuzumab‐resistant HER2‐positive breast cancer patients. Moreover, an equation for assessing the risk scores based on linear logistic regression models involving L‐arginine and arachidonic acid was created, which was beneficial for revealing metabolic changes in HER2‐positive breast cancer and enhancing current trastuzumab‐based therapy. In summary, we develop serum‐based metabolic biomarkers for diagnosis of HER2‐positive breast cancers and predicts the therapeutic effects of trastuzumab therapy.

13 March 2023 in Talanta
Verified
Journal Article
Closed access
ZWZhongcheng Wang
Zhongcheng Wang
LLLi Li
Li Li
YKYuqiong Kuang
Yuqiong Kuang
JYJiang Yao
Jiang Yao
FXFeifei Xu
Feifei Xu
C.Chen Yun .
Chen Yun .